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 Pathogenesis of hepatitis C virus (HCV) infection:  role of   genetic, 
immunologic and environmental factors  in HCV-related liver disease and  
in  symptomfree HCV carriers.  
 
Hepatitis C virus (HCV)   infection   is  a  major global health problem: 170 million  
subjects  are suffering   from chronic HCV  infection worldwide, of whom  five million in 
Europe and  about 70.000 in Hungary.    About 80 % of   patients  with acute HCV  infection   
go on  to  chronic hepatitis, from which  later  cirrhosis and/or hepatocellular carcinoma  may 
develop,  representing the most frequent  indication  of liver transplantation.  
       The outcome of HCV infection is  highly variable  from spontaneous   viral  clearance to    
symptomfree HCV carrier state with  persistently normal  alanine aminotransferase (ALT),    
or  to  chronic hepatitis and cirrhosis.  Some cases   in HCV infection show  rapid progression 
– while others  remain  „healthy” carriers.   It is not completely  understood   what may  be the  
exact  cause  of the different  outcome,   but it is suggested, that partly    direct   viral  
cytopathy,   partly  host-related  genetically  determined immune mechanisms   as well as 
environmental  factors  are  responsible   for the HCV-induced  tissue injury.        
      Since  a strong   NK and  T-cell  response  is essential  for the  clearance  of HCV,   
genetic factors,  as well as  the  type of the immune response  are of    particular  importance  
in the pathogenesis.   In addition, environmental  factors  may  also be  capable of  modifying 
the host’s response  and  the outcome   of   HCV infection.    
     We  investigated   some of these  factors,   such   as haemochromatosis gene mutations,  
genetic polymorphism  of   CTLA4  and angiotensin converting enzyme (ACE)  genes,   
features  of  NK and T cell  functions  and  viral  coinfections,   in  different forms  of chronic 
HCV   infection, that is  in   symptomfree HCV carriers  with  persistently  normal  alanine 
amino transferase (ALT)  and  in  patients  with chronic hepatitis C,     treated with  Peg-IFN 
+  Ribavirin  (RBV) therapy..  
    We wanted to elucidate  the potential causes    determining   the differences  between  the 
above mentioned   groups   of    HCV infected   individuals, as well as   between  rapid, early  
or  slow  responders    and  non-responders  to antiviral  therapy.      
 
Genetic  studies 
 
The natural history   of  HCV  infection  remains controversial.  Chronic   hepatitis C  is   
typically characterised by slowly   progressive hepatic fibrosis. However it is  recognised, that  
some patients  do not progress,   while   others  rapidly develop cirrhosis.    It  is  difficult to 
assess  an  individual’s risk   of   progressive  liver disease.   Such  prognostic uncertainty  and 
variation  in the response to the  infective agent,  suggest  a genetic  component   to the 
outcome  of  HCV  infection. Thus,  among factors, that  influence  the rate of progression,   
the genetic predisposition  may be crucial.   
 
HFE  gene mutations  
We  have shown, that  the allele frequency  of  haemochromatosis gene  mutations (C282Y  
and H63D)  in  patients with chronic HCV  hepatitis  did not  differ  from  that of the normal  
Hungarian population. 
 
CTLA4  polymorphism 
CTLA4  is  a T cell  surface molecule,  an inhibitory  T cell   receptor,   expressed  on 
activated  and regulatoy  T  lymphocytes. Its  binding   partners,   CD80  and CD86  are     
expressed  on professional antigen presenting cells. Binding  CD28 molecule   on antigen  
presenting cell,    CTLA4    is a   negative  regulator  of  T cell activation,    playing a role   in    
maintenance of   peripheral self tolerance.  The  lack  of  CTLA 4  -   or   its certain  single 
nucleotide polymorphisms (SNPs)  such as   -318>T in the promoter region  and  +49A>G in 
the first exon,  resulting  in CTLA4 functional  abnormality, -   impairs  the control   of  T cell 
response,   predisposes  to  loss   of  self tolerance,  and can lead to excessive (uncontrolled)   
immune  reactions, even  autoimmune diseases, e.g. immune  thyreoiditis.   
      Since CTLA4 polymorphisms  can contribute to  development of  excessive  immune 
reactions,  it is tempting to speculate, that the same genetic variations   may protect from  
infections  in  other  individuals. Thus,  it  can be hypothetised, that  the same polymorphisms  
may be predictive  of   a favourable outcome   of treatment  in  HCV  patients  On the  other 
hand,  it may  be  related to  immune thyroiditis,   the  known   extrahepatic  complication of 
HCV  infection  as well as side effect of interferon therapy.   We have   investigated  the role  
of  SNPs  -318   and +49   in patients  with different  types  of   HCV infection,    in 
symptomfree „healthy”  HCV carrier state,  in  patients  with active  chronic hepatitis C,  
responders and non-responders  to antiviral tratment.  We wanted to  evaluate    the influence  
of these polymorphisms  on the outcome of  IFN-RBV based antiviral therapy   and  the  
immune mediated   side effects  of  the  treatment.  Up to now,  we  have found  no differences  
concerning  CTLA4 polymorphisms   between  “healthy” virus  carriers   and   patients with  
active HCV hepatitis,  as well  as  between  responders    and  non-responders   to  antiviral   
treatment.   
 
Angiotensin converting enzyme  (ACE)  gene  polymorphism 
Since   progressive    fibrosis   is a key element  of  HCV induced  liver disease  and  the  
renin-angiotensin system (RAS)   and angiotensin II   in particular,   play an importan role   
in the regulation  of fibrosis   in several   organs,    the relationship   of  hepatic fibrosis and 
RAS sysem  have been  suggested.  
  Angiotensin II  (AGII)  is   known as a principal  effector molecule of renin-angiotensin 
system, and it   also  mediates   production of  TGF-β1.    AG II  induces  expression  of 
TGF-β1  through  ANG II  type 1 receptor.   TGF-β1  increases  collagen  deposition  with 
accumulation   of extracellular matrix.  by controlling  transcriptional regulation  of fibrillar 
collagens.  Through  this  mechanism  ANG II  has been implicated    in the development  of 
fibrosis  in  renal and cardiac diseases, and  probably  similar mechanisms are at work  in  
liver cirrhosis  as well.    Recently the  presence of angiotensin receptors  was  shown  even  
on  hepatic stellate cells.   
    Many  functional  polymorphisms   in the genes  of the RAS  have been described   and  
postulated to contribute  to the   inter-individual  variation  in development of several   renal 
an cardiovascular diseases,   but yet   not  in   liver cirrhosis.  
    First  we studied the ACE  gene  I/D  polymorphisms    in  patients with chronic  hepatitis  
C, and  assessed  their effect   on  the course of the  HCV-disease, in  PEG-IFN + RBV treated  
patients.  It was  found,  that  among  HCV-patients who  responded  with  sustained 
virological response (SVR) to the antiviral therapy, the ACE D/D  mutant  occurred   in  
51.8%    vs  in   non-responders  of   23.1%,  suggesting  a  beneficial  effec of   ACE deletion  
on the  outcome  of  anti-HCV treatment.   Further  studies  are  warranted  to  explore  the  
background  of this finding. 
 
Immunological  studies,  fibrosis  and oxidative stress  
 
Natural killer cell (NK)  activity, perforin expression and  expression of CD81 molecule. 
Impaired NK cell activity has been proposed as a mechanism contributing to viral persistence 
in hepatitis C virus (HCV) infection.  We have shown  that in patients with  hepatitis C,   the  
natural killer (NK) activity of  the peripheral blood  mononuclear cells  (PBMCs)  was  
significantly lower as compared  not only  to normal control,   but   to  symptomfree  virus 
carriers   and   to  those,  who  responded to antiviral  (PEG-IFN  + ribavirin, RBV)   therapy  
with  complete  sustained  viral clearance.    PEG-IFN + RBV  treatment resulted in  elevation 
of  NK activity  of  PBMCs even  after  one week  of therapy  and remined  elevated during 
the  entire   treatment  period. 
    It was also demonstrated, that  the   frequency   of   perforin-positive   cytotoxic  CD3+ T 
cells  was lower  in  chronic  hepatitis C patients  as compared to  healthy virus carries. On  
the antiviral treatment,  the number of   perforin-positive T cells  increased, and  this  rise  was  
sustained  only  in those  who  were able to  clear  the  virus.  
    We  have  shown  the overexpression of CD81  molecule,  a surface co-receptor  for  HCV,  
on  peripheral blood  NK and B cells of   patients  with  active hepatitis C.  At the same time,  
in   healthy   HCV  carriers  the  expression of  CD81  was  decreased   as compared  to 
patients  with  active  hepatitis  C.    PEG-IFN + RBV   treatment  resulted  in  decreased  
CD81 expression  in   patients  with sustained virological response (SVR) 
   
Natural killer (NK)  cell function, activator receptors, regulatory T cells and TGFbeta1 
 Since  NKG2D as an important activator receptor of NK cells, has a pivotal position in both 
innate and adaptive immunity and as it is expressed not only on NK cells, but also on CD8+ T 
cells, we analyzed whether decreased NK activity corresponds to a dysregulated expression of 
NKG2D on  NK and  CD8+ T cells.  As regulatory T (Treg) cells are an important source of 
TGFbeta1, correlations between the percentage of Treg cells, plasma TGFbeta1 levels and 
NKG2D expression of NK and T cells were also studied.    
     The percentage of peripheral CD4+CD25high+Treg cells, NKG2D+ NK and T cells were 
determined by flow cytometry in  patients with chronic hepatitis C, in sustained virological 
responders (SVR)  previously treated with interferon (IFN) and in  healthy controls. 
  Results: In patients with chronic HCV hepatitis the activating receptor NKG2D expression 
was significantly  downregulated both on NK  and on T cells compared to healthy controls. 
This impaired expression of NKG2D was associated with increased proportion of 
CD4+CD25high+ Treg cells  and increased  TGFbeta1 levels  compared to control group. 
TGFbeta1 levels inversely correlated with the surface expression of NKG2D on NK cells. In 
contrast, the percentage of Treg cells, TGFbeta1 levels  and  the expression of NKG2D  in 
sustained virological responders was comparable to that of healthy controls.  
Conclusion: Our data present the first evidence that TGFbeta1 - secreted by regulatory T cells 
- is responsible for impaired NK cell function via down-regulating NKG2D activating 
receptor in chronic HCV hepatitis. Thus, TGFbeta antagonism or soluble NKG2D ligands 
may provide the basis of a novel antiviral  therapy to improve the function of NK and T cells.   
 
Phenotypes   and cytokine production  of  peripheral  blood  mononuclear cells 
Since less is known of the immunologic basis of rapid virological response (RVR) to IFN + 
RBV therapy  in chronic hepatitis  C,   we compared the phenotypes and cytokine production 
of peripheral blood mononuclear cells of rapid, slow and non-responders before treatment 
initiation.  Fifty patients with chronic HCV hepatitis before and at 1, 3 months of PEG-IFN+ 
RBV treatment were studied. The percentage of CD4, CD8, CD56, CD19, Treg, CD14 cells 
and TNFalpha, IL-2, IL-6, IFNgamma, IL-4, IL-10 production of LPS stimulated monocytes 
and PMA+ionomycine stimulated peripheral blood lymphocytes were determined by Flow 
Cytometry.  Baseline, LPS-induced TLR4 activation of the monocytes resulted in  
significantly higher Th1 type cytokine (TNFa:and IL6) production in rapid responders,  
compared to slow responders  and also to non-responders. Rapid HCV RNA clearance was 
also associated with decreased Th2 type cytokine production of lymphocytes. IL-4 and IL-10 
production of lymphocytes were significantly higher in slow responders  compared to rapid 
responders. TNFalpha production of monocytes was predictive for rapid virological response. 
While PEG-IFN and  RBV treatment increased IL-2, IFNgamma, TNFalpha production in 
slow responders, it had no effect on non-responders. An elevated TNFa and IL-6 production 
of TLR4 stimulated monocytes, increased IFNg and diminished IL-4 and IL-10 production of 
peripheral blood lymphocytes were associated with rapid virological response.  
Conclusion: Pretreatment TLR4 activation of the monocytes induced significantly higher Th1 
cytokine production in rapid responders compared to patients with lack of RVR, suggesting 
that modulation of TLR activity and cytokine production in non-responders may play 
important role in new therapeutic strategies. Determination of cytokine production may help 
identify patients more likely to respond to antiviral therapy as well as provide a rationale for 
the further design and use of immunotherapeutic approches. 
 
Fibrosis markers 
 
Since in the outcome of chronic hepatitis C virus (HCV) infection the progression of hepatic 
fibrosis is essential, and IFN treatment is supposed to inhibit fibrogenesis, we wanted to 
compare changes in three non-invasive fibrosis markers in chronic HCV hepatitis. Plasma 
levels of TGF-beta1 and hyaluronic acid (HA) were determined by ELISA, procollagen-III-
peptide (P-III-P) levels by RIA in symptomfree HCV carriers  and in  patients with chronic 
hepatitis C before the antiviral treatment and 1, 3, 6 and 12 months thereafter. Twenty two 
patients became responders (R), 27 patients were non-responders (NR).  Correlation between 
TGF-beta1, HA, P-III-P levels and the histological activity and the fibrosis score  in liver 
biopsy was  evaluated. Pretreatment plasma TGF-beta1, HA and P-III-P levels were 
significantly (p<0,01) increased in both responder and non-responder  HCV-patients 
compared to controls. HA levels correlated with fibrosis score, TGF-beta1 with histological 
activity index.  PEG-IFN + RBV treatment decreased  both TGF-beta1 and HA levels, not 
only in responders but also in non-responders. The reduction of fibrosis marker levels was 
more considerable after 6 months of antiviral therapy,  and remained  sustained  even 6 
months after the treatment.  PEG-IFN plus Ribavirin treatment decreased TGF-beta1 and HA 
levels independently of virological response.   In symptomfree  HCV carriers   levels of 
fibrosis  markers   did not differ from the  normal  control.    
Conclusion:  that antiviral treatment with PEG-IFN plus  RBV   in chronic hepatitis C  may 
have  antifibrotic   effect  even  in  virological non-responders.  
 
Oxidative stress 
 
Effects  of  silymarin  supplementation  in PEG-IFN  + RBV treated  chronic hepatitis C.    
    Since oxidative stress may play a pathogenetic role  in  chronic hepatitis C  and  the 
sustained virological response   to antiviral therapy  is  limited  in  HCV1 genotype infection,   
a double blind study  was performed  in PEG-IFN  + RBV  treated  HCV1 patiens,  to assess   
the efficacy  of  the supplementation  with  an  antioxidant  flavonoid, silymarin.   
    Thirty-two   naive  HCV1 positive  patients  with biopsy proven chronic hepatitis C,  to be 
treated with  PEG-IFN + RBV have been randomized:  group A):  16 patients were  given the 
antiviral therapy    for  6-12 months plus  placebo for the first  3 months,    group  B):  16  
patients    were  treated  with pegylated interferon  +  ribavirin for 6-12 months    plus   
silymarin  2x166 mg/day  was  given  for  3 months.    Serum alanine aminotransferase (ALT) 
and    HCV-RNA   levels, as well as parameters of oxidative stress  such  as  plasma  or red 
blood cell hemolysate   malondiadehyde (MDA),   superoxide dismutase (SOD), glutathione 
peroxidase (GPX),  catalase  and myeloperoxidase (MPX)  were  determined  at   0,  1, 3, 6 
and 12  months  during the treatment.   sustained virological response  as  undetectable serum 
HCV RNA  was  evaluated  after  24 weeks  of   the  end  of therapy.  In  the silymarin group   
a more rapid  decrease  in MDA level,  as well as  a marked decrease  in SOD and an  increase  
in MPX  activity    at   month 12  were   found.   
Conclusion: Although  silymarin  supportation to antiviral therapy  improved  oxidative stress,    
it was not able to affect  favourably  the  sustained virological response.   These  contradictory  
findings may be related  to  randomization bias,  as patients  in the study  group B  have  more 
negative predictors  of virological  response:  they  were  older  with   higher fibrosis  score  
and  even  with  more  severe    pretreatment  baseline  oxidative stress.  Regarding the  
recently  published  in vitro experiments  with silybinin on HCV replication  as well as    the 
newest  convincing   clinical  observations,   we  suggested  futher  studies  with more than 
three times  higher doses silymarin  in  controlled  trials    to  asses the effect of silimarin 
supportation  in anti-HCV-treated partients. 
 
Environmental  factor: Co-infection  with  SEN virus  in  HCV-patients   
 
   It has been suggested, that   co-infections  with  hepatotropic viruses  may  play a  role   in 
the different  outcomes  of  HCV   infection.   Yet,   the implications  of these  co-infections  
in the clinical course  are   unclear,   and it   should also  be  elucidate,  whether  the response 
type  to   anti-HCV  treatment  is   influenced  or not   by  their simultaneous  presence. 
      We determined the prevalence  of  SENV DNA  D/H in  patients   with chronic HCV  
infection,  and  evaluated  the effect of  SENV infection  on the  PEG-IFN + RBV  induced  
sustained virological response (SVR). In addition, the  effect of  the   anti-HCV  therapy  on  
SENV elimination was assessed. Three groups of  HCV patients  have been studied:   group 
A):  19  individuals   with  HCV-RNA positivity  and  persistently   normal  serum ALT   
level,  group   B):  48   patients   with   chronic active hepatitis C,  and  group C):  18   pts 
with HCV cirrhosis.  Thirty-four  healthy individuals   served  as  control. Serum  HCV-RNA  
was  measured  by   Cobas Amplicor HCV Monitor 2.2 Roche,    presence  and  quantity  of  
SENV-D  and   SENV-H strains    was  determined  by   Real-time PCR  using Taqman   
probes.  In  the healthy controls,   SENV-D  prevalence  was  8.8%  and  SENV-H   38.2%,   
in   group  A)  42.1%  and  31.5%),   in  group B)  43.7%  and  66.6%,    in group C)  27.7% 
and  66.6%,   respectively. Of  19  HCV patients with   SVR  to  PEG-IFN + RBV,  42.1%  
were   SENV-D  carrier     and    63.1%  were  SENV-H  positive,   while  in   29  non-
responders   44.8%   and   68,9%,   respectively.   SVR  occurred  among   SENV  D/H  DNA  
positive patients    in 37.8%,  in SENV-D positive cases 33%,   in   SENV D/H  negative  
patients  in  45% of  cases, respectively.   SENV-D co-infection seems to be a negative 
predictor of  virological response in PEG-IFN + RBV treated chronic hepatitis C.   The   anti-
HCV treatment   resulted  in   SENV D/H   elimination    in  40.5% of  cases.  In the group  of  
non-responders  to PEG-IFN + RBV therapy,   half of  SENV-H   positive  patients  showed  
an  elevation  of  SENV-H  DNA titer  during the course of  hepatitis C.  
Conclusion:  The  prevalence   of   SENV   infection    is   higher  in  patients  with  chronic  
active C  hepatitis/cirrhosis    compared   to  healthy  controls.   The efficacy  of  anti-HCV  
treatment  was  unfavourably  affected   by   the   presence  of  SENV-D,  but not  SENV-H.    
SENV   seemed  to be sensitive to  PEG-IFN + RBV   therapy.      
 
 
 
 
 
 
 Summary 
 
1. Neither  haemochromatosis gene mutations,   nor CTLA4  polymorphisms  influence  the  
activity  of  HCV-related  liver disease,  however,  ACE gene deletion has a  favourable  
effect  on   the outcome  of  anti-HCV treatment  in  chronic hepatitis C. 
 
2. Overexpression of CD81 molecule on NK and B cells, as well  as  transforming growth 
factor beta1 (TGFbeta1) secreted by regulatory T cells,  and downregulated NKG2D 
activating receptor  on  cytotoxic effector cells, may   play a privotal role in the  impaired cell 
mediated immunity  in active  HCV infection   
 
3.  Plasma  TGFbeta1, hyalurinic acid  and procollagene-III-peptide  levels – as markers of 
fibrogenesis - are  elevated  in  active hepatitis C patients,   but not  symptomfree carriers.  
Interferon  + ribavirin  therapy  may inhibit   fibrogenesis   independently   of  virological 
response  in chronic  HCV hepatitis.    
 
4. SEN  virus   co-infection, - as an additive  environmetal factor -  frequently  occuring  in  
HCV  patients,  can  decrease  the  effect  of  anti-HCV treatment.      
 
